CoviVac vaccination induces production of neutralizing antibodies against Delta and Omicron variants of SARS-CoV-2

  1. Liubov Kozlovskaya
  2. Ilya Gordeychuk
  3. Anastasia Piniaeva
  4. Anastasia Kovpak
  5. Anna Shishova
  6. Aleksandr Lunin
  7. Elena Shustova
  8. Vasiliy Apolokhov
  9. Ksenia Fominykh
  10. Yuri Ivin
  11. Alla Kondrashova
  12. Viktor Volok
  13. Irina Tcelykh
  14. Aleksandra Siniugina
  15. Aydar Ishmukhametov

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Vaccines are proven to be an effective tool in prophylaxis of severe COVID-19, but emerging mutated SARS-CoV-2 variants constantly challenge vaccines’ protectivity. We have evaluated the ability of the sera from individuals vaccinated with two variants of inactivated vaccine CoviVac and COVID-19 convalescents (May-December 2020) to neutralize SARS-CoV-2 variants Delta and Omicron. Four groups of serum samples (CoviVac vaccinees; COVID-19 convalescents; mice immunized with CoviVac preparations based on prototype B.1.1 strain and Delta variant) were evaluated in virus neutralization test against SARS-CoV-2 heterologous B.1.1 virus, Delta and Omicron variants. CoviVac preparations based on B.1.1 and Delta induced neutralizing antibodies against SARS-CoV-2 B.1.1 and two variants of concern. We observed a decrease in neutralization capacity in the sera from CoviVac (based on B.1.1 strain) vaccinees: 57.1% samples had detectable neutralizing antibodies against Delta and 61.9% against Omicron variants. Sera samples of all (100%) mice immunized with a candidate vaccine based on the SARS-CoV-2 Delta variant strain had neutralizing antibodies against all tested strains.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2022.02.10.22270781: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsField Sample Permit: COVID-19 convalescent sera samples were collected in Russia from May to December 2020 from convalescent donors according to the state program of plasma collection to be used for treatment.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Serum samples: Serum samples were collected from Phase I/II Clinical trials participants, who tested negative for SARS-CoV-2 antibodies in NT and in ELISA before the trials (ClinicalTrials.gov, NCT05046548) and were vaccinated with CoviVac (0.5 ml) intramuscularly twice with 14 days period.
    SARS-CoV-2
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    After 3-5 passages in Vero cells, viruses were stored as infected cell suspension at –70°C. 2.2.
    Vero
    suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)
    Experimental Models: Organisms/Strains
    SentencesResources
    BALB/c mice were vaccinated with CoviVac preparation based on B.1.1 strain (GISAID EPI_ISL_428851) intramuscularly (0.5 ml) twice with 14 days interval, serum samples were collected 7 days after the last immunization for vaccine immunogenicity testing as described previously [7].
    BALB/c
    suggested: None
    Software and Algorithms
    SentencesResources
    The CoviVac candidate vaccine based on Delta variant was prepared using the Delta variant strain (GISAID EPI_ISL_8799478) by the same technology as CoviVac [7].
    CoviVac
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT05046548CompletedThis is a Double-blind, Placebo-controlled, Randomized Study…

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2022.02.10.22270781 on medRxiv